All In Biotech

Drug Trial Radar · NCT05256745

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

RAGE Inhibition to Decrease Cancer Therapy Related Cardio Toxicity in Women With Early Breast Cancer

Last checked: Nov 19, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Jun 6, 2023

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Georgetown UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RAGE pathway will decrease anthracycline related cardiotoxicity and chemotherapy related cognitive decline.

Conditions

  • Cancer Related Cognitive Decline
  • Non-metastatic Breast Cancer

Interventions

  • TTP488Drug

    Each Azeliragon capsule is 5mg, and is to be taken in the morning with food as indicated in each cohort.

  • ddAC/ddTDrug

    Dose dense doxorubicin plus cyclophosphamide followed by paclitaxel (ddAC/ddT) for 8 cycles, administered per USPI (Unites States Prescribing Information) Label

  • TCDrug

    Docetaxel plus cyclophosphamide (TC) for 4-6 cycles, administered per USPI (Unites States Prescribing Information) Label

  • TCHPDrug

    Docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)for 6 cycles, administered per USPI (Unites States Prescribing Information) Label

  • Chemotherapy regimen that includes ddACDrug

    can include: (1) weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide, administered per USPI (Unites States Prescribing Information) Label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of unacceptable toxicityTime frame: 1 cycle (Cohort 1 and 4 each cycle is 14 days; Cohort 2 and 3 each cycle is 21 days)
  2. Incidence of severe AE graded according to the CTCAE v.5Time frame: 1 cycle (Cohort 1 and 4 each cycle is 14 days; Cohort 2 and 3 each cycle is 21 days)
  3. Incidence of chemotherapy dose interruption, dose modification, dose discontinuationTime frame: 1 cycle (Cohort 1 and 4 each cycle is 14 days; Cohort 2 and 3 each cycle is 21 days)
  4. Change in Troponin levelTime frame: Cohort 1 and 4: cycle 3 and cycle 4, day 1 and day 2 of 14 day cycle; Cohort 2 and 3:cycle 5 and cycle 6, day 1 and day 2 of 21 day cycle]

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Georgetown Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia · Recruiting

  • Medstar Washington Hospital Center

    Washington D.C., District of Columbia · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.